Management of Overactive Bladder: Defining the Role of Extended-Release Tolterodine

By Keam S.J.   Perry C.M.  

Disease Management & Health Outcomes, Vol. 12, Iss. 2, 2004-01 ,pp. : 121-142

Adis International

Access to resources Recommend Favorite

Non-Pharmacological Treatments for Chronic Pain: A Disease Management Context

By Dennis C. Turk  

Disease Management & Health Outcomes, Vol. 13, Iss. 1, 2005-01 ,pp. : 19-30

Adis International

Access to resources Recommend Favorite

Specific delivery of kinase inhibitors in nonmalignant and malignant diseases

By van Beuge Marike Marjolijn   Poelstra Klaas   Prakash Jai  

Expert Opinion on Drug Delivery, Vol. 9, Iss. 1, 2012-01 ,pp. : 59-70

Informa Healthcare

Access to resources Recommend Favorite

Expected clinical benefits of paliperidone extended-release formulation when compared with risperidone immediate-release

By Pani Luca   Marchese Giorgio  

Expert Opinion on Drug Delivery, Vol. 6, Iss. 3, 2009-03 ,pp. : 319-331

Informa Healthcare

Access to resources Recommend Favorite

Cost Effectiveness of Guanfacine Extended-Release versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder: Application of a Matching-Adjusted Indirect Comparison

By Erder M. Haim  

Applied Health Economics and Health Policy, Vol. 10, Iss. 6, 2012-11 ,pp. : 381-395

Adis International

Access to resources Recommend Favorite